Assessment of 50 CLL-specific antibody combinations identified three (CD5/CD19 with CD20/CD38, CD81/CD22 and CD79b/CD43) with low inter-laboratory variation and false-detection rates. Experienced ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

This composite flow cytometric panel illustrates the bone marrow of a newly diagnosed primary plasma cell leukemia patient demonstrating CD38 +, λ-a-restricted, CD20-plasma cells.

In September 2021, the Center for Drug Evaluation (CDE) of China proclaimed that Roche’s CD3/CD20 bispecific antibody RO7030816 (Mosunetuzumab) received clinical trial implied permission for the ...

At present, the most widely researched monoclonal antibody for MM targets CD38. However, newer developments of bispecific antibodies that target CD38/CD3 are in the pipeline – taking full ...

In all, 88% of participants achieved a complete response with CD20-CD19-directed therapy. Additionally, every patient received their treatment within 8 to 12 days of starting lymphodepletion.

The business is stopping further research on imvotamab, a CD20 x CD3 bispecific antibody, and IGM-2644, a CD38 x CD3 bispecific antibody. Phase 1b rheumatoid arthritis and systemic lupus ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

CD38 is an enzyme with NAD-depleting and intracellular signaling activity expressed on the cell surface, in intracellular compartments and in mitochondria, and is linked to inflammatory and autoimmune ...